In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nordic Nanovector ASA

Latest From Nordic Nanovector ASA

Appointments: Top-Level Changes At J&J, Roche, Pierre Fabre, Nordic Nanovector, Inthera And DDF

This week's announcements include changes at the top of Johnson & Johnson, Roche, Pierre Fabre, Nordic Nanovector, Inthera Bioscience and the Dementia Discovery Fund, plus new board appointments at Dova, Easton, Destiny Pharma and Abivax.

Appointments BioPharmaceutical

Appointments: Celgene, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector And Axcella Health Announce New Hires

Companies announcing executives moves this week include Celgene with a new CFO, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector, Axcella Health, and NDA Group. The British Generic Manufacturers Association also announced a new chair.

Appointments BioPharmaceutical

Nordic Nanovector Starting Pivotal Trial With Lead Asset Betalutin In R/R FL

Norwegian biotech is starting PARADIGME Phase IIb trial testing Betalutin in follicular lymphoma.

Cancer Clinical Trials

Appointments: Novartis And GSK Fill Key R&D Roles, Celgene Board Changes And Others

This week's announcements include Novartis's replacement for Vas Narasimhan as head of global development, GlaxoSmithKline's new head of worldwide business development for pharmaceuticals research & development, new board members at Celgene, an interim CEO at Nordic Nanovector, and changes at Vectura, PureTech Health and Exicure.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Nordic Nanovector AS
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Nordic Nanovector ASA
  • Senior Management
  • Eduardo Bravo, CEO
    Tone Kvale, CFO
    Jostein Dahle, PhD, CSO
    Marco Renoldi, MD, COO
    Lisa Rojkjaer, MD, CMO
    Lars Nieba, PhD, CTO
  • Contact Info
  • Nordic Nanovector ASA
    Phone: 22 18 33 01
    Kjelsåsveien 168 B
    Oslo, 0884